Data Insights
By Company Name
No filters selected
By Disease Name
No filters selected
By Drug Name
No filters selected
By Themes
No filters selected
Showing 1 results out of 1
Data Insights
Pralsetinib by Blueprint Medicines for Solid Tumor: Likelihood of Approval
Pralsetinib is under clinical development by Blueprint Medicines and currently in Phase II for Solid Tumor. According to GlobalData, Phase...